Biologics for ANCA-Associated Vasculitis

ISSN: 2212-4055 (Online)
ISSN: 1871-5281 (Print)

Volume 15, 6 Issues, 2016

Download PDF Flyer

Inflammation & Allergy - Drug Targets (Discontinued)

Formerly: 'Current Drug Targets - Inflammation & Allergy

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Kurt S Zaenker
Institute of Immunology and Experimental Oncology
University Witten/Herdecke
Stockumerstraße 10
Witten, 58448

View Full Editorial Board

Purchase Articles Order Reprints

Biologics for ANCA-Associated Vasculitis

Inflammation & Allergy - Drug Targets (Discontinued), 13(4): 275-287.

Author(s): Giuseppe Murgia, Davide Firinu, Paolo E. Manconi and Stefano R Del Giacco.

Affiliation: Department of Medical Sciences “M. Aresu”, Unit of Internal Medicine, Allergy and Clinical Immunology, University of Cagliari, Azienda Ospedaliero Universitaria, SS 554-Bivio Sestu, I-09042 Monserrato (CA), Italy.


The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a group of necrotizing vasculitides with a potential fatal outcome. Conventional therapy is based on the use of glucocorticoids (GCs) and cyclophosphamide (CYC), which is associated with severe toxic effects and is unable to control the disease activity in some refractory and relapsing cases. Several authors focused their efforts on the identification of safe and more efficient drugs, primarily investigating biological agents. Rituximab (RTX) demonstrated to be an alternative to CYC as remission-induction therapy for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) in two clinical controlled randomized trials. Contrasting data emerged regarding anti-TNF-α agents, and their use should be limited to some selected refractory or relapsing cases. Mepolizumab (MPZ) and Omalizumab (OMZ) are potentially beneficial treatments for patients with eosinophilic granulomatosis with polyangiitis (EGPA). Hereby, we perform a review focused on the use of biological drugs for AAV treatment.


ANCA, ANCA associated vasculitis, biological agents, biological therapy, biologics, monoclonal antibodies, rituximab.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 13
Issue Number: 4
First Page: 275
Last Page: 287
Page Count: 13
DOI: 10.2174/1871528113666140702094456
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science